Gelatin-based nanoparticle targets molecular 'seesaw' behind lung cancer drug resistance

A fundamental discovery by University of Missouri scientists could help solve one of the most frustrating challenges in treating lung cancer: Why do some patients initially respond to drug treatment, only for it to stop working 18 months later?